Prognostic value of VISTA in solid tumours: a systematic review and meta-analysis

Sci Rep. 2020 Feb 14;10(1):2662. doi: 10.1038/s41598-020-59608-w.


In the last few years, V-domain Ig-containing suppressor of T cell activation(VISTA) has been reported as a prognostic biomarker in articles including various solid tumours. However, their conclusions have been controversial. For this reason, we performed this meta-analysis to further verify the prognostic value of VISTA in solid tumours. All relevant literature was identified from PubMed, Embase, the Cochrane Library and Web of Science. Ten studies, including 2, 440 patients, were eligible for the analysis. The pooled results showed that high expression of VISTA was associated with favourable overall survival (OS) than that seen with low expression of VISTA (7 studies, hazard ratio (HR) = 0.75, 95% confidence interval (CI): 0.66-0.86, P < 0.001). In addition, high expression of VISTA significantly correlated with high numbers of CD8 (+) tumour infiltrating lymphocytes (TILs) (3 studies, risk ratio (RR) = 1.80, 95% CI: 1.41-2.31, P < 0.001). In conclusion, these results indicate that VISTA is a potential prognostic biomarker in solid tumours.

Publication types

  • Meta-Analysis
  • Systematic Review

MeSH terms

  • B7 Antigens / metabolism*
  • CD8-Positive T-Lymphocytes / immunology
  • Disease-Free Survival
  • Female
  • Humans
  • Lymphocyte Count
  • Lymphocytes, Tumor-Infiltrating / immunology
  • Male
  • Neoplasms / diagnosis*
  • Neoplasms / immunology
  • Neoplasms / metabolism*
  • Prognosis
  • Publication Bias


  • B7 Antigens
  • VSIR protein, human